BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Conditions
Non Small Cell Lung Cancer
What is the purpose of this trial?
The study is designed to develop individualized targeted therapy based on the identification and validation of specific molecular pathways of non-small cell lung cancer (NSCLC.) To address these new targeted therapeutic approaches, we propose to implement a translational lung cancer research program entitled, “BATTLE-2: Biomarker-integrated Approaches of Targeted Therapy of Lung Cancer Elimination-2,” and provide a strong rationale-based targeted treatment strategy. The program required that all eligible subjects with advanced NSCLC undergo a core biopsy of their tumors and applied biomarkers in the selection of individualized targeted therapy.
Participation Guidelines
- Age:
- 18 and older
- Gender:
- Both
Click here for detailed information about who can participate in this trial.
- Sponsor:
- MD Anderson Cancer Center
- Dates:
- Last Updated:
- Study HIC#:
- 1108008990
Clinicaltrials.gov ID: Yale0186992
Investigators
Roy Herbst, MD, PhD
Principal Investigator
Anne Chiang, MD, PhD
Sub-Investigator
Daniel Morgensztern, MD
Sub-Investigator
Marianne Davies,
Sub-Investigator
Rebecca Sipples,
Sub-Investigator
Sarah Goldberg, MD, MPH
Sub-Investigator
Scott Gettinger, MD
Sub-Investigator
